View Item 

Show simple item record

When should tests for unexpected antibodies be done during pregnancy?

dc.contributor.authorJudd, W. Johnen_US
dc.date.accessioned2011-11-10T15:38:42Z
dc.date.available2012-09-04T15:27:57Zen_US
dc.date.issued2011-07en_US
dc.identifier.citationJudd, W. John (2011). "When should tests for unexpected antibodies be done during pregnancy?." Transfusion 51(7). <http://hdl.handle.net/2027.42/87118>en_US
dc.identifier.issn0041-1132en_US
dc.identifier.issn1537-2995en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/87118
dc.publisherBlackwell Publishing Incen_US
dc.publisherWiley Periodicals, Inc.en_US
dc.titleWhen should tests for unexpected antibodies be done during pregnancy?en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationume‐mail: johnjudd12@gmail.com 
Department of Pathology 
University of Michigan Medical Center 
Ann Arbor, MIen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/87118/1/j.1537-2995.2011.03212.x.pdf
dc.identifier.doi10.1111/j.1537-2995.2011.03212.xen_US
dc.identifier.sourceTransfusionen_US
dc.identifier.citedreferenceJudd WJ, The 2003‐2004 Scientific Section Coordinating Committee. Guidelines for prenatal and perinatal immunohematology. Bethesda (MD): American Association of Blood Banks; 2005.en_US
dc.identifier.citedreferenceAmerican College of Obstetricians and Gynecologists. Management of alloimmunization in pregnancy. ACOG Practice Bulletin No. 75. Obstet Gynecol 2006; 108: 457 ‐ 64.en_US
dc.identifier.citedreferenceOrtho Pharmaceutical Corporation. Directions for use: Rh o (D) Immune Globulin (Human), Rh o GAM. Raritian, NJ: Ortho Diagnostics, May, 1968.en_US
dc.identifier.citedreferenceOrtho Diagnostic Systems. Directions for use: Rh o (D) Immune Globulin (Human), Rh o GAM. Raritian, NJ: Ortho Diagnostics, August, 1981.en_US
dc.identifier.citedreferenceBowman JM, Chown B, Lewis M, Pollock JM. Rh alloimmunization during pregnancy: antenatal prophylaxis. Can Med Assoc J 1978; 118: 623 ‐ 6.en_US
dc.identifier.citedreferenceBowman JM, Pollock JM. Antenatal prophylaxis of Rh immunoglobulin: 28 weeks' gestation service program. Can Med Assoc J 1978; 118: 627 ‐ 30.en_US
dc.identifier.citedreferenceHoward H, Martlew V, McFayden I, Clarke C, Duguid J, Bromilow I, Eggington J. Consequences for fetus and neonate of maternal red cell alloimmunisation. Arch Dis Child Fetal Neonatal Ed 1998; 78: F62 ‐ 6.en_US
dc.identifier.citedreferenceBritish Committee for Standards in Immunohematology. Blood Transfusion Task Force. Guidelines for blood grouping and red cell antibody testing during pregnancy. Transfus Med 1996; 6: 71 ‐ 4.en_US
dc.identifier.citedreferencePrice TH. Standards for blood banks and transfusion services. 26th ed. Bethesda (MD): American Association of Blood Banks; 2009.en_US
dc.identifier.citedreferenceShulman IA, Calderon C, Nelson JM, Nakayama R. The routine use of Rh‐negative reagent red cells for the identification of anti‐D and the detection of non‐D red cell antibodies. Transfusion 1994; 34: 666 ‐ 70.en_US
dc.identifier.citedreferenceAdeniji AA, Fuller I, Dale T, Lindow SW. Should we continue screening rhesus D positive women for the development of atypical antibodies in late pregnancy? J Matern Fetal Neonatal Med 2007; 20: 59 ‐ 61.en_US
dc.identifier.citedreferenceRothenberg JM, Weirermiller B, Dirig K, Hurd WW, Schilder J, Golichowski A. Is a third trimester antibody screen in Rh+ women necessary? Am J Manag Care 1999; 5: 1145 ‐ 50.en_US
dc.identifier.citedreferenceHeddle NM, Klama L, Frasseto R, O'Hoski P, Leaman B. A retrospective study to determine the risk of red cell alloimmunization and transfusion during pregnancy. Transfusion 1993; 33: 217 ‐ 20.en_US
dc.identifier.citedreferenceAndersen AS, Praetorius L, Jorgensen HL, Lylloff K, Larsen KT. Prognostic value of screening for irregular antibodies late in pregnancy in rhesus positive women. Acta Obstet Gynecol Scand 2002; 81: 407 ‐ 11.en_US
dc.identifier.citedreferenceBowell PJ, Allen DL, Entwistle CC. Blood group antibody screening tests during pregnancy. Br J Obstet Gynecol 1986; 93: 1038 ‐ 43.en_US
dc.identifier.citedreferenceDajak S, Stefanovic V, Capkun V. Severe hemolytic disease of the fetus and newborn caused by red blood cell antibodies undetected at first‐trimester visit. Transfusion 2011; 51: 1380 ‐ 8.en_US
dc.identifier.citedreferencede Silva M, Englefriet CP, Reesink HW. Current status of immunoprophylaxis with anti‐D immunoglobulin. Vox Sang 2003; 85: 328 ‐ 37.en_US
dc.identifier.citedreferenceBracey AW, Moise KJ. Hemolytic disease of the fetus or newborn: treatment and prevention. In: Simon TL, Dzik WH, Snyder EL, Stowell CP, Strauss RG, editors. Rossi's principles of transfusion medicine. 3rd ed. Philadelphia (PA): Williams and Wilkins; 2002. p. 428 ‐ 48.en_US
dc.identifier.citedreferenceKoelewijn JM, Vrikkotte TGM, de Haas M, van der Schoot CE, Bonsel GJ. Risk factors for the presence of non‐rhesus D red blood cell antibodies in pregnancy. BJOG 2009; 116: 655 ‐ 64.en_US
dc.identifier.citedreferenceBlumberg N. Beyond ABO and D antigen matching: how far and for whom? Transfusion 1990; 39: 482 ‐ 4.en_US
dc.identifier.citedreferenceZimring JC, Welniak L, Semple J, Ness PM, Slichter SJ, Spitalnik SL; NHLBI Alloimmunization Working Group. Current problems and future directions of transfusion‐induced alloimmunization: summary of an NHLBI working group. Transfusion 2011; 51: 435 ‐ 41.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1537-2995.2011.03212.x.pdf
Size:
49.94KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.